IPP Bureau
QIAGEN and NVIDIA partner on AI drug discovery
By IPP Bureau - May 21, 2026
Collaboration integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights’ curated biomedical knowledge bases
Hansa Biopharma licenses IDEFIRIX to SERB Pharmaceuticals in €115 million deal
By IPP Bureau - May 21, 2026
SERB has a substantial European commercial presence and a successful track record in critical care and rare disease commercialization
India reaffirms commitment to global women and child health agenda at WHA 2026
By IPP Bureau - May 21, 2026
Minister J.P. Nadda holds bilateral meeting with Helen Clark, Board Chair of the Partnership for Maternal, Newborn and Child Health in Geneva
ZenMD launches India-focused clinical AI platform for doctors and hospitals
By IPP Bureau - May 21, 2026
Solutions designed to help clinicians reduce administrative burden, improve diagnostic accuracy, and spend more time with patients
Drug Safety Symposium 2026 to focus on real-world impact of pharmacovigilance
By IPP Bureau - May 21, 2026
The event is expected to attract more than 100 senior professionals from pharmaceutical companies, CROs, regulatory agencies, and technology organisations
Pfizer advances next-gen pneumococcal vaccine after strong Phase 2 infant data
By IPP Bureau - May 21, 2026
Pfizer says the broader dataset across all 25 serotypes strengthens confidence that the program can meet non-inferiority thresholds in its upcoming Phase 3 pediatric trials
Bristol Myers Squibb & Anthropic redraw biopharma with Claude-powered enterprise AI
By IPP Bureau - May 21, 2026
BMS is moving beyond conversational AI into what it describes as “agentic” systems
National Genomics Infrastructure becomes first global certified core lab for Epigenica’s EpiFinder platform
By IPP Bureau - May 21, 2026
NGI will deliver full end-to-end workflows using both EpiFinder cNUC and EpiFinder GenomePro
Lilly's retatrutide delivers 30% weight loss in Phase 3 TRIUMPH-1 trial
By IPP Bureau - May 21, 2026
All three dose levels, 4 mg, 9 mg and 12 mg, successfully met the primary and key secondary endpoints in 80 weeks
Dr. Abhigyan Upadhyay to lead Platinum Industries foray into life sciences
By IPP Bureau - May 21, 2026
Dr. Upadhyay brings over 25 years of global leadership experience across life sciences, regulated manufacturing, diagnostics, and research-led environments
Boston Scientific invests $1.5 billion in MiRus for TAVR expansion
By IPP Bureau - May 20, 2026
Deal includes exclusive option to acquire MiRus’ SIEGEL TAVR system for an additional $3 billion upon milestone achievements
Amanta Healthcare reports 42% YoY growth in FY26 profit
By IPP Bureau - May 20, 2026
The company’s revenue stood at Rs. 287.68 crore, reflecting a 4.7 percent increase over Rs. 274.71 crore reported in FY25
Zydus Lifesciences reports FY26 revenue of Rs. 27,148 crore, Q4 revenue up 16%
By IPP Bureau - May 20, 2026
Company’s FY26 EBITDA rses 20% to Rs. 8,475 crore; Net profit grows 15% amid strong operational performance
Sukino Continuum appoints Sheshadri Vasan as President
By IPP Bureau - May 20, 2026
Sheshadri brings with him extensive leadership experience spanning healthcare, diagnostics, telecom, and consumer goods industries
